ETF Holdings Breakdown of VCYT

Stock NameVeracyte Inc
TickerVCYT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS92337F1075
LEI529900ESWZRHXOW27Z37

News associated with VCYT

Tudor Investment Corp ET AL Sells 20,531 Shares of Veracyte, Inc. (NASDAQ:VCYT)
Tudor Investment Corp ET AL lessened its holdings in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 50.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,342 shares of the biotechnology company’s stock after selling 20,531 shares during the quarter. […] - 2025-05-08 09:44:55
Veracyte, Inc. (NASDAQ:VCYT) Shares Bought by Hsbc Holdings PLC
Hsbc Holdings PLC grew its stake in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 14.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,084 shares of the biotechnology company’s stock after acquiring an additional 1,406 shares during the quarter. Hsbc Holdings PLC’s holdings […] - 2025-05-08 09:07:00
Price T Rowe Associates Inc. MD Has $1.92 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)
Price T Rowe Associates Inc. MD raised its stake in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 3.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,414 shares of the biotechnology company’s stock after acquiring an additional 1,816 shares during the quarter. […] - 2025-05-08 07:58:52
Voya Investment Management LLC Decreases Position in Veracyte, Inc. (NASDAQ:VCYT)
Voya Investment Management LLC decreased its position in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 7.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,066 shares of the biotechnology company’s stock after selling 1,781 shares during the period. Voya Investment Management […] - 2025-05-07 08:58:57
Brokerages Set Veracyte, Inc. (NASDAQ:VCYT) PT at $42.60
Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the […] - 2025-05-07 05:19:08
Veracyte, Inc. (NASDAQ:VCYT) Short Interest Up 22.5% in April
Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 5,110,000 shares, a growth of 22.5% from the March 31st total of 4,170,000 shares. Based on an average daily volume of 956,000 shares, the short-interest ratio is […] - 2025-05-05 05:36:53
First Trust Advisors LP Has $8.08 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)
First Trust Advisors LP boosted its position in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 155.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 204,042 shares of the biotechnology company’s stock after acquiring an additional 124,275 shares during the quarter. First Trust Advisors […] - 2025-04-30 08:52:59
Russell Investments Group Ltd. Has $2.60 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)
Russell Investments Group Ltd. increased its position in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 233.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,541 shares of the biotechnology company’s stock after purchasing an additional 45,876 shares during the quarter. […] - 2025-04-18 07:53:09
Veracyte, Inc. (NASDAQ:VCYT) Shares Bought by Alliancebernstein L.P.
Alliancebernstein L.P. grew its stake in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,420 shares of the biotechnology company’s stock after purchasing an additional 2,000 shares during the period. Alliancebernstein L.P. owned […] - 2025-04-15 07:52:54
Veracyte (NASDAQ:VCYT) Given New $37.00 Price Target at Guggenheim
Veracyte (NASDAQ:VCYT – Get Free Report) had its price objective cut by stock analysts at Guggenheim from $45.00 to $37.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price objective points to a potential upside of 22.31% from the stock’s current price. […] - 2025-04-11 07:46:55
Veracyte (NASDAQ:VCYT) Shares Gap Down After Analyst Downgrade
Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) gapped down before the market opened on Wednesday after Guggenheim lowered their price target on the stock from $45.00 to $37.00. The stock had previously closed at $28.88, but opened at $27.22. Guggenheim currently has a buy rating on the stock. Veracyte shares last traded at […] - 2025-04-10 05:40:48
Norges Bank Takes $8.93 Million Position in Veracyte, Inc. (NASDAQ:VCYT)
Norges Bank acquired a new position in Veracyte, Inc. (NASDAQ:VCYT – Free Report) in the fourth quarter, Holdings Channel reports. The firm acquired 225,602 shares of the biotechnology company’s stock, valued at approximately $8,934,000. A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in VCYT. […] - 2025-04-09 07:56:52
Veracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Vanguard Group Inc.
Vanguard Group Inc. increased its position in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 6.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 8,211,612 shares of the biotechnology company’s stock after buying an additional 463,098 shares during the quarter. Vanguard Group Inc. owned about 0.11% of Veracyte worth $325,180,000 as of its most […] - 2025-04-04 08:04:58
Corebridge Financial Inc. Lowers Stake in Veracyte, Inc. (NASDAQ:VCYT)
Corebridge Financial Inc. decreased its position in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 7.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 38,204 shares of the biotechnology company’s stock after selling 2,885 shares during the quarter. Corebridge Financial Inc.’s holdings in Veracyte were worth $1,513,000 at the end of the […] - 2025-04-03 08:49:01
Prudential Financial Inc. Has $4.83 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)
Prudential Financial Inc. raised its position in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 602.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,003 shares of the biotechnology company’s stock after acquiring an additional 104,639 shares during the period. […] - 2025-04-01 08:32:46
AlphaQuest LLC Sells 8,728 Shares of Veracyte, Inc. (NASDAQ:VCYT)
AlphaQuest LLC trimmed its stake in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 88.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,151 shares of the biotechnology company’s stock after selling 8,728 shares during the quarter. […] - 2025-03-21 08:07:01
PNC Financial Services Group Inc. Has $1.01 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)
PNC Financial Services Group Inc. grew its position in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 9.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 25,439 shares of the biotechnology company’s stock after acquiring an additional 2,115 shares during the period. PNC Financial Services Group Inc.’s holdings in Veracyte were worth $1,007,000 […] - 2025-03-17 07:56:54
Principal Financial Group Inc. Buys 2,074 Shares of Veracyte, Inc. (NASDAQ:VCYT)
Principal Financial Group Inc. raised its stake in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 6.8% in the fourth quarter, Holdings Channel reports. The firm owned 32,560 shares of the biotechnology company’s stock after acquiring an additional 2,074 shares during the quarter. Principal Financial Group Inc.’s holdings in Veracyte were worth $1,289,000 as of its […] - 2025-03-06 09:59:25
Truist Financial Corp Has $460,000 Holdings in Veracyte, Inc. (NASDAQ:VCYT)
Truist Financial Corp cut its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 6.5% in the fourth quarter, HoldingsChannel reports. The fund owned 11,622 shares of the biotechnology company’s stock after selling 804 shares during the quarter. Truist Financial Corp’s holdings in Veracyte were worth $460,000 as of its most recent SEC […] - 2025-03-04 08:30:47
Veracyte (NASDAQ:VCYT) Shares Up 9.9% Following Analyst Upgrade
Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) traded up 9.9% during mid-day trading on Wednesday after UBS Group raised their price target on the stock from $46.00 to $49.00. UBS Group currently has a buy rating on the stock. Veracyte traded as high as $35.95 and last traded at $36.77. 451,819 shares traded […] - 2025-02-28 10:08:59
Handelsbanken Fonder AB Lowers Position in Veracyte, Inc. (NASDAQ:VCYT)
Handelsbanken Fonder AB trimmed its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 4.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,206 shares of the biotechnology company’s stock after selling 1,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in […] - 2025-02-28 09:25:09
Veracyte (NASDAQ:VCYT) Price Target Raised to $49.00 at UBS Group
Veracyte (NASDAQ:VCYT – Free Report) had its price target increased by UBS Group from $46.00 to $49.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. VCYT has been the topic of several other reports. The Goldman Sachs Group reissued a “neutral” rating and issued […] - 2025-02-26 09:20:54
Veracyte, Inc. (NASDAQ:VCYT) Receives $42.00 Average PT from Analysts
Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to […] - 2025-02-21 06:18:45
Veracyte (NASDAQ:VCYT) Stock Rating Lowered by StockNews.com
Veracyte (NASDAQ:VCYT – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday. Other research analysts have also issued reports about the stock. Scotiabank raised their target price on shares of Veracyte from $40.00 to $44.00 and gave […] - 2025-02-18 06:16:51

VCYT institutional holdings

The following institutional investment holdings of VCYT have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 51,354USD 1,602,758
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 6,963USD 217,315 1.2%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 93,029USD 2,903,435
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 37,276USD 1,163,384
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 37,276USD 1,163,384 1.2%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 260USD 8,115
Total =226,158 USD 7,058,391
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.